nct_id,official_title,intervention_name,target,indication,toxicity_profile,phase,enrollment,status
NCT00000000,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1538,Terminated
NCT00000001,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,305,Completed
NCT00000002,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1229,Suspended
NCT00000003,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 1,211,Recruiting
NCT00000004,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 1,1169,Recruiting
NCT00000005,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,1905,Suspended
NCT00000006,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,153,Recruiting
NCT00000007,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,2376,Recruiting
NCT00000008,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,937,Completed
NCT00000009,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,755,Terminated
NCT00000010,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,455,Suspended
NCT00000011,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1908,Suspended
NCT00000012,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,3062,Recruiting
NCT00000013,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1374,Recruiting
NCT00000014,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1771,Recruiting
NCT00000015,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,2377,Suspended
NCT00000016,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,778,Terminated
NCT00000017,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,684,Recruiting
NCT00000018,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,354,Suspended
NCT00000019,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,4662,Recruiting
NCT00000020,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,489,Completed
NCT00000021,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,2293,Completed
NCT00000022,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,1841,Suspended
NCT00000023,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,1270,Terminated
NCT00000024,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1545,Terminated
NCT00000025,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,4880,Suspended
NCT00000026,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,303,Suspended
NCT00000027,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1783,Completed
NCT00000028,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1642,Suspended
NCT00000029,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,808,Suspended
NCT00000030,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,4434,Terminated
NCT00000031,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1413,Completed
NCT00000032,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,2886,Completed
NCT00000033,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,1395,Suspended
NCT00000034,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,4200,Recruiting
NCT00000035,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1802,Terminated
NCT00000036,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,333,Terminated
NCT00000037,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,1246,Terminated
NCT00000038,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,249,Terminated
NCT00000039,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,138,Recruiting
NCT00000040,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,195,Suspended
NCT00000041,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,282,Suspended
NCT00000042,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,562,Suspended
NCT00000043,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,1480,Terminated
NCT00000044,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,3688,Suspended
NCT00000045,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,480,Completed
NCT00000046,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,1224,Recruiting
NCT00000047,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,34,Completed
NCT00000048,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,158,Completed
NCT00000049,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,1072,Recruiting
NCT00000050,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,1855,Recruiting
NCT00000051,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2090,Suspended
NCT00000052,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 2,213,Completed
NCT00000053,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,3569,Suspended
NCT00000054,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1399,Completed
NCT00000055,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 4,2879,Completed
NCT00000056,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,409,Suspended
NCT00000057,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,1603,Terminated
NCT00000058,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1810,Completed
NCT00000059,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,123,Completed
NCT00000060,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,360,Suspended
NCT00000061,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,1851,Suspended
NCT00000062,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,796,Completed
NCT00000063,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,3827,Terminated
NCT00000064,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,1368,Recruiting
NCT00000065,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,139,Completed
NCT00000066,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,122,Suspended
NCT00000067,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,136,Completed
NCT00000068,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,1238,Completed
NCT00000069,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,1082,Recruiting
NCT00000070,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,1288,Completed
NCT00000071,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,2236,Recruiting
NCT00000072,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,563,Suspended
NCT00000073,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,3845,Terminated
NCT00000074,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,958,Completed
NCT00000075,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1056,Terminated
NCT00000076,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,663,Recruiting
NCT00000077,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,1392,Suspended
NCT00000078,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,4433,Completed
NCT00000079,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,948,Recruiting
NCT00000080,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1842,Completed
NCT00000081,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,577,Terminated
NCT00000082,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1489,Terminated
NCT00000083,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,4240,Suspended
NCT00000084,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,209,Suspended
NCT00000085,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,27,Terminated
NCT00000086,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,1423,Suspended
NCT00000087,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,4694,Completed
NCT00000088,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1955,Recruiting
NCT00000089,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1729,Terminated
NCT00000090,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,900,Recruiting
NCT00000091,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,3087,Completed
NCT00000092,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,1416,Recruiting
NCT00000093,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,4686,Suspended
NCT00000094,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1915,Recruiting
NCT00000095,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1825,Suspended
NCT00000096,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,1528,Terminated
NCT00000097,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 2,566,Recruiting
NCT00000098,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,417,Suspended
NCT00000099,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,1692,Suspended
NCT00000100,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,1964,Recruiting
NCT00000101,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,836,Terminated
NCT00000102,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,2000,Terminated
NCT00000103,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,4492,Terminated
NCT00000104,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 1,1816,Terminated
NCT00000105,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,413,Completed
NCT00000106,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2931,Terminated
NCT00000107,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,808,Recruiting
NCT00000108,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1471,Suspended
NCT00000109,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,765,Suspended
NCT00000110,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,2671,Completed
NCT00000111,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,3445,Terminated
NCT00000112,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,4641,Recruiting
NCT00000113,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,3205,Recruiting
NCT00000114,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,3426,Completed
NCT00000115,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,1821,Suspended
NCT00000116,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,3909,Suspended
NCT00000117,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1066,Suspended
NCT00000118,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,601,Terminated
NCT00000119,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1397,Terminated
NCT00000120,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,321,Completed
NCT00000121,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,993,Completed
NCT00000122,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,4815,Recruiting
NCT00000123,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,3373,Recruiting
NCT00000124,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,1848,Completed
NCT00000125,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 2,380,Suspended
NCT00000126,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,1898,Completed
NCT00000127,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1661,Suspended
NCT00000128,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,3725,Suspended
NCT00000129,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,1403,Suspended
NCT00000130,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,2125,Terminated
NCT00000131,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,2059,Terminated
NCT00000132,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1481,Terminated
NCT00000133,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,2851,Terminated
NCT00000134,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,303,Recruiting
NCT00000135,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,1351,Recruiting
NCT00000136,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,3439,Terminated
NCT00000137,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,3506,Completed
NCT00000138,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,3290,Completed
NCT00000139,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,4007,Completed
NCT00000140,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,3294,Suspended
NCT00000141,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,1019,Recruiting
NCT00000142,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,4078,Completed
NCT00000143,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,3412,Recruiting
NCT00000144,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1294,Completed
NCT00000145,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,191,Suspended
NCT00000146,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,1588,Completed
NCT00000147,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,2781,Recruiting
NCT00000148,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,2864,Suspended
NCT00000149,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,2166,Completed
NCT00000150,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1554,Completed
NCT00000151,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,1351,Completed
NCT00000152,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 1,1964,Recruiting
NCT00000153,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 1,1292,Recruiting
NCT00000154,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,989,Completed
NCT00000155,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,972,Terminated
NCT00000156,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,1260,Completed
NCT00000157,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,985,Completed
NCT00000158,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,3349,Recruiting
NCT00000159,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,228,Terminated
NCT00000160,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,1650,Completed
NCT00000161,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,3135,Completed
NCT00000162,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,203,Suspended
NCT00000163,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,907,Terminated
NCT00000164,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,911,Recruiting
NCT00000165,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,4508,Suspended
NCT00000166,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,4953,Terminated
NCT00000167,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,1721,Completed
NCT00000168,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,2097,Suspended
NCT00000169,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2855,Completed
NCT00000170,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,1589,Suspended
NCT00000171,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,2216,Terminated
NCT00000172,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,4653,Completed
NCT00000173,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,195,Recruiting
NCT00000174,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,4648,Recruiting
NCT00000175,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,3771,Completed
NCT00000176,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,1915,Suspended
NCT00000177,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,4864,Terminated
NCT00000178,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,3585,Terminated
NCT00000179,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,2319,Terminated
NCT00000180,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,267,Recruiting
NCT00000181,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,1541,Recruiting
NCT00000182,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,1532,Suspended
NCT00000183,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,923,Recruiting
NCT00000184,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,759,Recruiting
NCT00000185,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1470,Recruiting
NCT00000186,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,131,Terminated
NCT00000187,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,940,Completed
NCT00000188,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,3945,Suspended
NCT00000189,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,1610,Completed
NCT00000190,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,1034,Completed
NCT00000191,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,706,Completed
NCT00000192,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1681,Terminated
NCT00000193,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,262,Suspended
NCT00000194,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1608,Suspended
NCT00000195,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,2535,Suspended
NCT00000196,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1268,Completed
NCT00000197,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,561,Completed
NCT00000198,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,375,Completed
NCT00000199,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,856,Suspended
NCT00000200,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2485,Completed
NCT00000201,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,2416,Suspended
NCT00000202,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1912,Terminated
NCT00000203,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,890,Completed
NCT00000204,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,1346,Recruiting
NCT00000205,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,166,Completed
NCT00000206,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,4974,Terminated
NCT00000207,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,979,Terminated
NCT00000208,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,4199,Suspended
NCT00000209,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1244,Completed
NCT00000210,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,2151,Completed
NCT00000211,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1989,Completed
NCT00000212,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1582,Recruiting
NCT00000213,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,2378,Recruiting
NCT00000214,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,4128,Completed
NCT00000215,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,3445,Terminated
NCT00000216,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,1776,Recruiting
NCT00000217,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,4158,Terminated
NCT00000218,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,951,Completed
NCT00000219,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,2748,Completed
NCT00000220,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,1366,Suspended
NCT00000221,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,404,Terminated
NCT00000222,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,3721,Completed
NCT00000223,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,4599,Recruiting
NCT00000224,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,4070,Completed
NCT00000225,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,1473,Recruiting
NCT00000226,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1151,Suspended
NCT00000227,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1743,Completed
NCT00000228,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1346,Recruiting
NCT00000229,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,4268,Terminated
NCT00000230,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,3968,Recruiting
NCT00000231,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,805,Recruiting
NCT00000232,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1789,Completed
NCT00000233,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,2884,Terminated
NCT00000234,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,2545,Suspended
NCT00000235,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,4512,Suspended
NCT00000236,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,4621,Suspended
NCT00000237,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,1645,Recruiting
NCT00000238,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2013,Suspended
NCT00000239,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,3974,Suspended
NCT00000240,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 2,1034,Completed
NCT00000241,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,922,Suspended
NCT00000242,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,225,Recruiting
NCT00000243,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 2,173,Suspended
NCT00000244,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,3356,Completed
NCT00000245,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,2694,Suspended
NCT00000246,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1284,Completed
NCT00000247,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,1963,Completed
NCT00000248,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,1577,Completed
NCT00000249,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1441,Terminated
NCT00000250,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 1,684,Completed
NCT00000251,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,3170,Suspended
NCT00000252,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1107,Suspended
NCT00000253,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,368,Recruiting
NCT00000254,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,2072,Suspended
NCT00000255,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,495,Suspended
NCT00000256,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,2191,Completed
NCT00000257,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,4577,Recruiting
NCT00000258,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,2930,Terminated
NCT00000259,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,3842,Terminated
NCT00000260,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,4058,Completed
NCT00000261,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,4785,Terminated
NCT00000262,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,2518,Completed
NCT00000263,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,166,Completed
NCT00000264,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2444,Recruiting
NCT00000265,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,1894,Recruiting
NCT00000266,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,1220,Completed
NCT00000267,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,3711,Completed
NCT00000268,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,1176,Completed
NCT00000269,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,3503,Recruiting
NCT00000270,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,1630,Terminated
NCT00000271,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,1447,Terminated
NCT00000272,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,2874,Completed
NCT00000273,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,308,Recruiting
NCT00000274,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,839,Suspended
NCT00000275,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,4495,Completed
NCT00000276,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,2247,Suspended
NCT00000277,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,1402,Recruiting
NCT00000278,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1288,Terminated
NCT00000279,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1346,Completed
NCT00000280,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,3444,Completed
NCT00000281,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,1957,Completed
NCT00000282,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,1051,Completed
NCT00000283,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,815,Suspended
NCT00000284,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,4911,Recruiting
NCT00000285,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,1727,Suspended
NCT00000286,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2391,Completed
NCT00000287,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,928,Suspended
NCT00000288,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,913,Terminated
NCT00000289,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,596,Suspended
NCT00000290,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,270,Suspended
NCT00000291,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1334,Completed
NCT00000292,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,2095,Recruiting
NCT00000293,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,160,Recruiting
NCT00000294,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1685,Recruiting
NCT00000295,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,1635,Completed
NCT00000296,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,286,Terminated
NCT00000297,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,1373,Completed
NCT00000298,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,753,Recruiting
NCT00000299,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,229,Recruiting
NCT00000300,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,279,Suspended
NCT00000301,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1547,Completed
NCT00000302,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,3065,Completed
NCT00000303,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1956,Completed
NCT00000304,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,3852,Completed
NCT00000305,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 4,3390,Suspended
NCT00000306,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,3733,Completed
NCT00000307,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,1315,Completed
NCT00000308,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,4895,Terminated
NCT00000309,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,3816,Suspended
NCT00000310,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1766,Recruiting
NCT00000311,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,1971,Suspended
NCT00000312,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,3366,Suspended
NCT00000313,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,3596,Terminated
NCT00000314,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,1350,Suspended
NCT00000315,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1723,Completed
NCT00000316,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,891,Terminated
NCT00000317,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 1,1221,Terminated
NCT00000318,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,2996,Suspended
NCT00000319,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,2659,Terminated
NCT00000320,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,336,Suspended
NCT00000321,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 1,737,Terminated
NCT00000322,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,4803,Recruiting
NCT00000323,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,1267,Terminated
NCT00000324,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 2,579,Terminated
NCT00000325,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,150,Recruiting
NCT00000326,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,670,Recruiting
NCT00000327,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 1,1548,Recruiting
NCT00000328,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,3816,Terminated
NCT00000329,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,2652,Terminated
NCT00000330,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,1829,Completed
NCT00000331,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1565,Completed
NCT00000332,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,3729,Suspended
NCT00000333,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,3492,Terminated
NCT00000334,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 1,726,Suspended
NCT00000335,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,4958,Suspended
NCT00000336,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,472,Recruiting
NCT00000337,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,35,Recruiting
NCT00000338,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,1591,Recruiting
NCT00000339,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,2787,Completed
NCT00000340,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 4,3627,Recruiting
NCT00000341,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,4462,Recruiting
NCT00000342,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,690,Suspended
NCT00000343,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 4,253,Suspended
NCT00000344,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,4816,Suspended
NCT00000345,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,3521,Terminated
NCT00000346,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,270,Terminated
NCT00000347,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,3064,Completed
NCT00000348,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,518,Suspended
NCT00000349,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,4392,Completed
NCT00000350,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,2881,Recruiting
NCT00000351,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,176,Completed
NCT00000352,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,1875,Terminated
NCT00000353,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,503,Completed
NCT00000354,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,1716,Recruiting
NCT00000355,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1576,Completed
NCT00000356,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,3900,Suspended
NCT00000357,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,2689,Recruiting
NCT00000358,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,980,Suspended
NCT00000359,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,4944,Completed
NCT00000360,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,655,Suspended
NCT00000361,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,136,Terminated
NCT00000362,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1340,Completed
NCT00000363,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,3890,Completed
NCT00000364,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,678,Suspended
NCT00000365,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,1981,Completed
NCT00000366,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1680,Terminated
NCT00000367,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,100,Recruiting
NCT00000368,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,4393,Recruiting
NCT00000369,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,2417,Suspended
NCT00000370,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,4997,Completed
NCT00000371,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,695,Completed
NCT00000372,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,2427,Terminated
NCT00000373,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,702,Completed
NCT00000374,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1897,Terminated
NCT00000375,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,1156,Completed
NCT00000376,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,2790,Recruiting
NCT00000377,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,1343,Suspended
NCT00000378,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,249,Terminated
NCT00000379,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 2,1967,Recruiting
NCT00000380,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,1672,Recruiting
NCT00000381,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,178,Terminated
NCT00000382,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1375,Terminated
NCT00000383,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1243,Suspended
NCT00000384,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,390,Recruiting
NCT00000385,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,861,Terminated
NCT00000386,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,2434,Suspended
NCT00000387,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,653,Suspended
NCT00000388,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,4772,Suspended
NCT00000389,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,3228,Suspended
NCT00000390,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1660,Recruiting
NCT00000391,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1333,Suspended
NCT00000392,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,1476,Completed
NCT00000393,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 1,1582,Recruiting
NCT00000394,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,4305,Recruiting
NCT00000395,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,1958,Recruiting
NCT00000396,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,318,Suspended
NCT00000397,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 4,4212,Terminated
NCT00000398,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,768,Terminated
NCT00000399,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 1,672,Completed
NCT00000400,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,301,Completed
NCT00000401,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,1236,Suspended
NCT00000402,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,1875,Completed
NCT00000403,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,1866,Recruiting
NCT00000404,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,1010,Terminated
NCT00000405,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,1098,Completed
NCT00000406,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,3844,Completed
NCT00000407,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,4988,Completed
NCT00000408,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,1491,Recruiting
NCT00000409,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,112,Terminated
NCT00000410,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,1634,Completed
NCT00000411,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,654,Completed
NCT00000412,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,456,Suspended
NCT00000413,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,233,Terminated
NCT00000414,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,2075,Completed
NCT00000415,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,1192,Completed
NCT00000416,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,1534,Suspended
NCT00000417,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1681,Recruiting
NCT00000418,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,402,Terminated
NCT00000419,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 1,1640,Recruiting
NCT00000420,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,2640,Suspended
NCT00000421,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,2175,Completed
NCT00000422,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,3024,Completed
NCT00000423,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,1119,Terminated
NCT00000424,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,3702,Suspended
NCT00000425,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,1036,Suspended
NCT00000426,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,776,Suspended
NCT00000427,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,1578,Terminated
NCT00000428,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 1,183,Terminated
NCT00000429,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,3752,Suspended
NCT00000430,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,2979,Suspended
NCT00000431,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 3,3663,Terminated
NCT00000432,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 1,1394,Suspended
NCT00000433,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,1971,Completed
NCT00000434,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,385,Recruiting
NCT00000435,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1614,Terminated
NCT00000436,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,4746,Completed
NCT00000437,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1410,Suspended
NCT00000438,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,3736,Completed
NCT00000439,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,1104,Terminated
NCT00000440,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,2383,Recruiting
NCT00000441,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1526,Recruiting
NCT00000442,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 4,4701,Completed
NCT00000443,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 3,3755,Recruiting
NCT00000444,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 3,4123,Recruiting
NCT00000445,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1766,Completed
NCT00000446,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 2,1860,Suspended
NCT00000447,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 3,2946,Completed
NCT00000448,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,2557,Recruiting
NCT00000449,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,4267,Recruiting
NCT00000450,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 2,1642,Recruiting
NCT00000451,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,315,Terminated
NCT00000452,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,3928,Recruiting
NCT00000453,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,154,Terminated
NCT00000454,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,4406,Suspended
NCT00000455,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,276,Terminated
NCT00000456,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,3916,Terminated
NCT00000457,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1592,Recruiting
NCT00000458,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,1722,Completed
NCT00000459,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 2,642,Recruiting
NCT00000460,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,1947,Terminated
NCT00000461,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,746,Terminated
NCT00000462,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 3,1125,Terminated
NCT00000463,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,1049,Recruiting
NCT00000464,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 2,370,Terminated
NCT00000465,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,1710,Completed
NCT00000466,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,1962,Terminated
NCT00000467,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,348,Suspended
NCT00000468,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 3,2574,Suspended
NCT00000469,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 4,2536,Suspended
NCT00000470,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 1,343,Suspended
NCT00000471,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 4,3904,Recruiting
NCT00000472,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 2,660,Terminated
NCT00000473,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,1171,Terminated
NCT00000474,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,673,Recruiting
NCT00000475,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,567,Suspended
NCT00000476,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,218,Completed
NCT00000477,Study of Adalimumab in Autoimmune,Adalimumab,TNF-alpha,Autoimmune,infection,Phase 4,3525,Recruiting
NCT00000478,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,4832,Terminated
NCT00000479,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,1040,Suspended
NCT00000480,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 3,4174,Completed
NCT00000481,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,4240,Suspended
NCT00000482,Study of Bevacizumab in Multiple cancers,Bevacizumab,VEGF,Multiple cancers,vascular,Phase 2,1214,Terminated
NCT00000483,Study of Rituximab in B-cell lymphoma,Rituximab,CD20,B-cell lymphoma,infusion_reactions,Phase 1,596,Suspended
NCT00000484,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 4,2440,Completed
NCT00000485,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,1197,Terminated
NCT00000486,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 4,3097,Completed
NCT00000487,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 1,1187,Recruiting
NCT00000488,Study of Tocilizumab in Rheumatoid arthritis,Tocilizumab,IL-6,Rheumatoid arthritis,infection,Phase 3,702,Suspended
NCT00000489,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,4604,Terminated
NCT00000490,Study of Ipilimumab in Melanoma,Ipilimumab,CTLA-4,Melanoma,immune_related,Phase 1,283,Completed
NCT00000491,Study of Cetuximab in Colorectal cancer,Cetuximab,EGFR,Colorectal cancer,skin_toxicity,Phase 3,2877,Terminated
NCT00000492,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,1253,Suspended
NCT00000493,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 1,112,Completed
NCT00000494,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 3,3980,Suspended
NCT00000495,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 2,691,Terminated
NCT00000496,Study of Pembrolizumab in Multiple cancers,Pembrolizumab,PD-1,Multiple cancers,immune_related,Phase 4,2551,Terminated
NCT00000497,Study of Daratumumab in Multiple myeloma,Daratumumab,CD38,Multiple myeloma,infusion_reactions,Phase 4,4711,Terminated
NCT00000498,Study of Blinatumomab in ALL,Blinatumomab,CD19/CD3,ALL,neurotoxicity,Phase 1,774,Terminated
NCT00000499,Study of Trastuzumab in Breast cancer,Trastuzumab,HER2,Breast cancer,cardiotoxicity,Phase 4,4881,Terminated
